The New England journal of medicine, 2019-07, Vol.381 (4), p.338-348
- Loriot, Yohann
- Necchi, Andrea
- Park, Se Hoon
- Garcia-Donas, Jesus
- Huddart, Robert
- Burgess, Earle
- Fleming, Mark
- Rezazadeh, Arash
- Mellado, Begoña
- Varlamov, Sergey
- Joshi, Monika
- Duran, Ignacio
- Tagawa, Scott T
- Zakharia, Yousef
- Zhong, Bob
- Stuyckens, Kim
- Santiago-Walker, Ademi
- De Porre, Peter
- O’Hagan, Anne
- Avadhani, Anjali
- Siefker-Radtke, Arlene O
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Loriot, Yohann
- Necchi, Andrea
- Park, Se Hoon
- Garcia-Donas, Jesus
- Huddart, Robert
- Burgess, Earle
- Fleming, Mark
- Rezazadeh, Arash
- Mellado, Begoña
- Varlamov, Sergey
- Joshi, Monika
- Duran, Ignacio
- Tagawa, Scott T
- Zakharia, Yousef
- Zhong, Bob
- Stuyckens, Kim
- Santiago-Walker, Ademi
- De Porre, Peter
- O’Hagan, Anne
- Avadhani, Anjali
- Siefker-Radtke, Arlene O
- Titel
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- Ist Teil von
- The New England journal of medicine, 2019-07, Vol.381 (4), p.338-348
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Erdafitinib, an inhibitor of fibroblast growth factor receptor, was tested in previously treated patients with advanced urothelial cancer with FGFR alterations. The objective response rate was 40%, with treatment-related adverse events of grade 3 or higher reported in nearly half the patients.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793, 1533-4406eISSN: 1533-4406DOI: 10.1056/NEJMoa1817323Titel-ID: cdi_hal_primary_oai_HAL_hal_02930806v1
- Format
- –
- Schlagworte
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents - administration & dosage, Antineoplastic Agents - adverse effects, Antitumor activity, Bladder cancer, Cancer, Chemotherapy, Creatinine, Drug dosages, Editorials, Enzyme inhibitors, Fibroblast growth factor receptor 1, Fibroblast growth factor receptors, Gene expression, Humans, Immune clearance, Immunotherapy, Kaplan-Meier Estimate, Kinases, Life Sciences, Metastases, Metastasis, Middle Aged, Mutation, Neoplasm Metastasis - drug therapy, Pharmaceutical sciences, Progression-Free Survival, Protein Kinase Inhibitors - administration & dosage, Protein-tyrosine kinase, Protein-Tyrosine Kinases - antagonists & inhibitors, Pyrazoles - administration & dosage, Pyrazoles - adverse effects, Quinoxalines - administration & dosage, Quinoxalines - adverse effects, R&D, Receptors, Fibroblast Growth Factor - antagonists & inhibitors, Receptors, Fibroblast Growth Factor - genetics, Research & development, Response rates, Survival, Treatment Outcome, Urologic Neoplasms - drug therapy, Urologic Neoplasms - genetics, Urologic Neoplasms - pathology, Urothelial carcinoma, Urothelium